AZTA azenta.com: Forward P/S Multiple

Reduced capital expenditures by biotech laboratories are weighing on sales, which is reflected in the forward P/S dynamics based on forecasts on the GURU.Markets chart, where the value 3.10 shows the current figure. High barriers to entry and minimal customer churn ensure the stability of Azenta, Inc. (AZTA). Meanwhile, the implementation of cryogenic robotics for the protection of genetic materials positions the company as the core infrastructure of modern cellular medicine.

azenta.com - AZTA Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Brooks Automation (AZTA)

- current price and projected stock value:

Stock Price Azenta|AZTA - Average Forecast Price

- company stock capitalization data:

Market Capitalization Brooks Automation|AZTA - Business Value

- issuer book value statistics:

Book Value per Share Azenta|AZTA - Book Valuation of Business|Market Capitalization to Book Value Ratio azenta.com|AZTA - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

AZTA - Annual Net Income|Future Profit Azenta, Inc.|AZTA - P/E Multiple|Forward P/E Multiple Azenta Life Sciences|AZTA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Brooks Automation|AZTA - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Azenta|AZTA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth azenta.com|AZTA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Azenta, Inc.

- sales volume and revenue indicators:

AZTA - Company Sales Volume|Company Future Sales Volume Azenta|AZTA - Market Cap to Sales Volume|Forward P/S Multiple Brooks Automation

Summary company analytics:Azenta (AZTA)

Logistics optimization for cryogenic equipment at Azenta, Inc. (AZTA) directly impacts the company's forward P/S dynamics. This indicator correlates current market capitalization with expected future sales volume, determining the premium paid for future growth. The calculation is based on projected revenue, allowing for an assessment of the business's fundamental margin of safety. The stability of this ratio confirms capital resilience and the adequacy of market expectations.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Varex Imaging Corp (VREX)|Forward P/S Multiple SMLR|Forward P/S Multiple Butterfly Corp (BFLY)|Price-to-Projected Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Projected Revenue Ratio|NNOX: Forward Price-to-Revenue Multiple|Forward Price to Sales QTRX (Quanterix Corp.)|MASS: Forward P/S Multiple|Market Cap to Future Revenue Ratio CapsoVision (CV)|Price-to-Projected Revenue Ratio MaxCyte, Inc.|RPID - Projected Price to Revenue|Forward Price-to-Revenue Multiple SEER (Seer)|Forward P/S Multiple Hyperfine Inc (HYPR)|Forward P/S Multiple FONR (FONAR Corp)|Market Cap to Expected Sales Ratio Daxor Corp (DXR)|MDAI - Price-to-Projected Revenue Ratio|Future Price to Revenue VIVS|Aclarion, Inc. (ACON) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Talis Biomedical Corp TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)